Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.62 |
| ▸ | HTT | P42858 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16135768 | 0.85 | ALDH1A1 (0.59) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135776 | 0.80 | ALDH1A1 (0.62) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135842 | 0.80 | ALDH1A1 (0.59) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135774 | 0.79 | ALDH1A1 (0.68) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL19546655 | 0.78 | ALDH1A1 (0.47) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135841 | 0.75 | ALDH1A1 (0.50) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL1395862 | 0.73 | ALDH1A1 (0.72) | ALDH1A1HTTLMNANPSR1TRPM8 | |
| SCHEMBL16135885 | 0.70 | SMN1; SMN2 (0.54) | ALDH1A1HTTLMNAGAANPSR1 | |
| SCHEMBL16135886 | 0.70 | ALDH1A1 (0.52) | ALDH1A1HTTLMNANPSR1TRPM8 | |
| SCHEMBL16135883 | 0.69 | ALDH1A1 (0.54) | ALDH1A1HTTLMNAGAANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9944603-B2 | Compounds and methods for the treatment of cystic fibrosis | FLATLEY DISCOVERY LAB, LLC (US) | 2018-04-17 | — | — | US | disclosed |
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | FLATLEY DISCOVERY LAB LLC (US) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313659-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS | CFTR, SERPINB1, ELANE | ALDH1A1 514/4885HTT 4260/4885LMNA 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.